Form 4: Verona Pharma Director Sells Shares in Acquisition

Verona Pharma director Anders Ullman reported the disposition of shares and derivative securities following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Anders Ullman, a Director of Verona Pharma plc, reported changes in his beneficial ownership of the company's securities.
• The transactions occurred on October 7, 2025, as a result of a Scheme of Arrangement under UK law, pursuant to a Transaction Agreement dated July 8, 2025.
• Verona Pharma plc is being acquired by Merck Sharp & Dohme LLC and its wholly-owned subsidiary, Vol Holdings LLC.
• At the effective time of the Scheme of Arrangement, each holder of Scheme Shares became entitled to receive $13.375 in cash per Ordinary Share.
• Holders of American Depositary Shares (ADSs), each representing eight Ordinary Shares, became entitled to receive $107 in cash per ADS.
• Mr. Ullman disposed of 358,856 Ordinary Shares due to the Scheme of Arrangement, resulting in zero direct beneficial ownership of Ordinary Shares.
• His time-based Restricted Share Unit (RSU) awards, covering 72,000 Ordinary Shares (equivalent to ADSs), fully vested and were converted into cash based on the ADS Consideration.
• Outstanding share options, with various exercise prices ($0.5038, $2.67, $1.9338, $0.775), also fully vested and were converted into cash if their exercise price was less than the ADS Consideration.

Sentiment

Score: 9

Explanation: The filing details the successful execution of an acquisition, resulting in a cash payout to shareholders and equity holders, which is generally a positive outcome for investors.

Positives

• The acquisition provides a clear cash payout to shareholders at $13.375 per Ordinary Share or $107 per ADS.
• The vesting and cash conversion of RSUs and in-the-money share options for management ensures a payout for their equity incentives.

Risks

• No specific risks for the ongoing entity are detailed, as the filing pertains to an acquisition where the primary risk (deal failure) has been resolved by the reported transactions.

Future Outlook

The filing indicates the completion of an acquisition, meaning Verona Pharma plc's independent future outlook is superseded by its integration into Merck Sharp & Dohme LLC. No forward-looking statements for Verona Pharma as an independent entity are provided.

Management Comments

• The transactions were executed 'pursuant to a transaction agreement, dated as of July 8, 2025' and 'pursuant to the terms of the Transaction Agreement'.

Industry Context

This filing reflects a significant M&A event in the biopharmaceutical sector, where a smaller company (Verona Pharma) is acquired by a major pharmaceutical player (Merck Sharp & Dohme LLC). Such acquisitions are common for companies with promising drug candidates or technologies, providing an exit for shareholders and integrating assets into larger portfolios.

Related Party Transactions

• The disposition of securities by Director Anders Ullman is a direct consequence of the company-wide acquisition by Merck Sharp & Dohme LLC, affecting all shareholders and equity holders.

Stakeholder Impact

• Shareholders: Received a cash payout of $13.375 per Ordinary Share or $107 per ADS.
• Employees (with equity awards): Restricted Share Units and in-the-money Share Options fully vested and converted to cash.

Next Steps

• The company's shares will likely be delisted following the completion of the acquisition, and it will cease to operate as an independent publicly traded entity.

Key Dates

Keywords

Verona Pharma, VRNA, Anders Ullman, Director, SEC Form 4, beneficial ownership, acquisition, merger, Merck Sharp & Dohme, Vol Holdings, Scheme of Arrangement, Restricted Share Unit, Share Options